Crestwood, KY, United States - Liberate Medical, a leading medical device company specializing in neuromuscular electrical stimulation technology for patients with pulmonary disorders, announced today that it has successfully raised $6.2 million in a Series B funding round. The round was led by Scientific Health Development, a prominent investor in the healthcare industry.

Liberate Medical is dedicated to improving the quality of care and reducing costs for patients with pulmonary disorders through the development of innovative medical devices. The company's headquarters is located in Crestwood, Kentucky, in the United States.

The primary focus of Liberate Medical is the development of their flagship product, the VentFree™ respiratory muscle stimulator. In patients undergoing invasive mechanical ventilation, the respiratory muscles often weaken, leading to a higher dependency on ventilator support. The VentFree™ device applies proprietary, non-invasive electrical stimulation to the expiratory muscles in synchronization with exhalation while the patient is on mechanical ventilation. This groundbreaking therapy is designed to combat abdominal muscle atrophy and accelerate the liberation of patients from mechanical ventilation.

"We are excited to have secured $6.2 million in funding through our Series B round, led by Scientific Health Development," said Angus McLachlan, Co-Founder of Liberate Medical. "This investment will fuel our efforts to advance the development of the VentFree™ respiratory muscle stimulator and bring our innovative technology to the market. We are committed to making a meaningful difference in the lives of patients with pulmonary disorders and revolutionizing the way they receive care."